With one of the largest, most robust pipelines in the industry – including more than 120 research projects and product candidates – MedImmune comprises nearly half of AstraZeneca’s overall R & D portfolio. It is AstraZeneca’s pathfinder in global biologics R & D.
The business is focused on three core therapeutic areas: Oncology; Respiratory, Inflammation and Autoimmune; and Cardiovascular and Metabolic Disease. But it is also opportunity-driven in Infectious Disease.
MedImmune has a flagship Cambridge presence under the inspired leadership of Jane Osbourn and 2,200 employees worldwide. It boasts one of the largest and most robust pipelines in the industry worldwide, including more than 120 research products and product candidates.